IDEXX (IDXX): Vet Visits Are Falling, It Grew 11 Points Faster. Is IDXX Stock a Buy?

IDEXX Laboratories, Inc. (IDXX) Q2 2026 — Reported August 4, 2026 BEFORE the US open for Q2 2026 (the quarter ended June 30, 2026). Revenue $1,216.6M, +9.7% reported and +9.0% organic, vs a ~$1.20B consensus. Diluted EPS $4.27, +17.6%, vs a $3.96 consensus - but $0.14 of that came from share-based-compensation tax benefits and $0.06 from currency. Gross margin 64.0% (+140bps reported, +120bps comparable); operating margin 35.0% (+140bps reported, +110bps comparable). CAG revenue $1,118.2M (+9.4%), CAG Diagnostics recurring revenue $974.7M (+11.0% reported, +10.3% organic), Water $58.6M (+14.8%), LPD $35.2M (+10.8%). Full-year 2026 guidance RAISED: revenue $4,700-4,745M (organic growth 8.5-9.7%, up from 7.7-9.7%), operating margin 32.3-32.5%, EPS $14.69-14.94 (from $14.45-14.90). Shares closed the prior regular session at $567.84 (+1.57%) BEFORE the release; the reaction session had not closed when this episode was recorded, with IDXX trading up roughly 3.5% in the pre-market. The stock is 26% below its $766.68 closing high of November 25, 2025 and 8% above its $526.44 closing low of June 30, 2026, and sits below its $620.50 two-hundred-day average. The fact that makes this quarter interesting: US same-store veterinary clinical visits have been FALLING for about three years - roughly -1.9% across 2025 and about -1% in Q1 2026 - yet IDEXX's US CAG Diagnostics recurring revenue grew 9.7% organically to $630.5M. That is an ~11 percentage point gap between the end market's foot traffic and this company's revenue, and the whole investment case lives inside it. We went looking for the obvious explanation - that it is just price - and the evidence says mostly NOT: VetLab consumables grew 13.6% organically on stated VOLUME gains and an 11% larger global premium instrument installed base, and reference lab grew 10.3% organically on higher testing volumes and net new customers. Only rapid assay, at +1.1%, is a price story - and that one is self-inflicted, with volumes cannibalised by IDEXX's own Catalyst Pancreatic Lipase test. Two more things almost nobody flagged. FIRST, the $0.31 EPS beat is really about $0.11 of operations: $0.14 was share-comp tax benefits and $0.06 currency, both disclosed in the release. SECOND, forward free cash flow is LOWER than trailing free cash flow - capex steps from ~$117M trailing to a guided ~$180M, which is why the company guides FCF to 90-100% of net income against the 110% it just delivered. THE CALL: AVOID (3/5, AN ELITE BUSINESS AT A PRICE THAT NEEDS PERFECTION) — base-case value ~$465.0 vs ~$567.84 today. KEY METRICS: - CALL: AVOID 3/5 - fair value ~$465 vs the $567.84 close (about -18%), and below the LOWEST price target on Wall Street ($620). This is NOT a criticism of the business, which is outstanding; it is a call on the price of entry. Base free cash flow is taken from the company's OWN guidance rather than from trailing results: FY2026 EPS of $14.82 at midpoint on ~79.4M shares is ~$1,176M of net income, and IDEXX guides FCF to 90-100% of net income = ~$1,117M. Grow that 11% a year for five years (ABOVE the 8.5-9.7% organic revenue guide, crediting 70-90bps of annual margin expansion plus a 1.5-2% buyback), then 7% for five more, then 3% forever, discounted at 8%: PV of 2027-2036 FCF $12,303M + PV of terminal value $25,201M = enterprise value $37,503M, less $772M net debt = $36,731M equity / 78.95M shares = ~$465. Bear $343, bull $590; probability-weighted 25/50/25 = ~$478. - REVERSE DCF - THE WHOLE ARGUMENT: at $567.84 the market capitalisation is ~$44.8B and enterprise value ~$45.6B - 40.8x FY2026E free cash flow of $1,117M, a 2.5% FCF yield, and 38.3x guided FY2026 EPS. To justify that at an 8% discount rate you need roughly 14% free cash flow growth for five years and then 10%. IDEXX itself guides 8.5-9.7% ORGANIC REVENUE growth and 12-14% EPS growth - and that EPS figure already contains 1.5-2% of share-count reduction. The market is therefore pricing an acceleration above what the company guides, with no discount for the possibility that utilisation growth decays as penetration matures. - THE DECOUPLING (the reason to own it): US CAG Diagnostics recurring revenue $630.5M, +9.7% organic, against US same-store clinical visits running roughly -1 to -2%. International CAG Diagnostics recurring +13.6% reported / +11.6% organic off a far lower penetration base. Mechanism, not price: IDEXX VetLab consumables $430.3M (+14.7% reported, +13.6% organic) on testing utilisation gains, new product launches, net new customers and an 11% expansion of the global premium instrument installed base; reference laboratory diagnostic and consulting services $406.7M (+10.6% reported, +10.3% organic) on higher testing volumes. IDEXX inVue Dx installed base surpassed 9,000 instruments with over 1,600 placements in the quarter. - THE RAZOR-AND-BLADE MATH: of $1,118.2M of CAG revenue, $974.7M is CAG Diagnostics recurring and $76.3M is recurring veterinary software - so ~94% of companion animal revenue is RECURRING. CAG capital instruments were only $47.2M, 4.2% of the segment. So the headline 'instrument sales fell 19.5%' is an $11.4M decline inside a $1,216.6M quarter, under 1% of the company, and the release attributes it to lapping the Q2 2025 broad availability of inVue Dx. The one genuinely soft line is rapid assay products: $101.6M, +1.3% reported and +1.1% organic, driven by NET PRICE with volumes pressured by adoption of IDEXX's own Catalyst Pancreatic Lipase Test. - MARGIN AND SEGMENT DETAIL: gross profit $779.1M at 64.0% (from 62.6%); total operating expense $353.5M (+9.9%, roughly in line with revenue) split S&M $171.3M, G&A $116.8M, R&D $65.4M; income from operations $425.6M at 35.0% (from 33.6%). Net income $338.4M; diluted shares 79,312K, down 2.1% from 80,994K. By segment: CAG operating income $393.3M at 35.2% (from 34.1%); Water revenue $58.6M at a 74.4% gross margin and 51.7% operating margin; LPD $35.2M at a 53.0% gross margin, swinging to a $2.4M operating profit from a $0.5M loss a year ago. Note margin seasonality - Q2 printed 35.0% against a full-year guide of 32.3-32.5%. - CASH, CAPEX AND THE BUYBACK: Q2 free cash flow $322.5M (more than double the $151.6M of a year ago); H1 free cash flow $556.8M vs $359.6M, from $613.4M of operating cash flow less $56.6M capex. Trailing twelve months: ~$1,372M operating cash flow less ~$117M capex = ~$1,255M FCF on ~$1,140M net income, 110% conversion. BUT 2026 capex is guided to ~$180M, so ~$123M lands in H2 - which is why FY2026 FCF is guided to just 90-100% of net income. Buybacks: 1,170K shares repurchased in the open market in H1 for $692.9M at an average of $592.41 (Q2 alone 582K shares at $570.72) - ABOVE the $567.84 close. The revolver rose from $398M to $519M; total debt $968.9M less $196.9M cash = $772M net debt against $1,612.6M of equity. - WHY WE ARE BELOW THE STREET: consensus is Buy - 13 buy / 8 hold / 1 sell across 22 analysts with live targets - at an average target of $723.33, median $750, high $800, low $620. The Street sees +27% upside; we see -18% downside. We DIFFER and are far more CAUTIOUS - but note WHERE: we do NOT dispute the franchise, the moat, the 64% gross margin, or the decoupling from visit volumes, and we modelled FCF growth ABOVE the company's own organic revenue guidance. The disagreement is entirely the reverse DCF. Note also that the brief for this episode listed CIK 832988 for IDEXX - that is SIGNET JEWELERS; the correct IDEXX CIK is 874716, and every figure here was read off the 8-K EX-99.1 filed under accession 0001104659-26-090033 after grepping it for the company name and the period. What to watch: Bullish: CAG Diagnostics recurring organic growth HOLDING double digits into 2027 while US clinical visits stabilise rather than fall. If visits merely stop shrinking our growth assumption is too low and fair value moves toward $560. Bearish: recurring organic growth decaying below 7% as premium-instrument penetration matures while capex stays at the new ~$180M level - that takes free cash flow growth into the high single digits and our number to roughly $390. Also watch the buyback price: $692.9M was spent in H1 at an average of $592.41, above where the stock trades today. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.